Novo Nordisks oral semaglutide 25 mg (Wegovy in a pill*) delivered 16.6% weight loss in people with obesity in a newly published study
Oral semaglutide 25 mg (the once-daily pill formulation of Wegovy®) achieved significant…
People taking Novo Nordisks Wegovy experienced reduced food noise and boosted mental well-being
Results from a real-world survey suggest that semaglutide for weight management (Wegovy®)…
Novo Nordisk A/S: Wegovy approved in the US for the treatment of MASH
Bagsværd, Denmark, 15 August 2025 – Novo Nordisk today announced that the US…
Novo Nordisk A/S: Mim8 prophylaxis treatment shown to be well-tolerated when switching from emicizumab in people with haemophilia A in new phase 3 data presented at the ISTH 2025 Congress
New FRONTIER5 data show that a direct switch to investigational Mim8 (denecimig)…
Novo Nordisk: Higher dose of Wegovy provided average weight loss of 21% in people with obesity with a third achieving 25% or more according to data presented at ADA
Higher dose of Wegovy® provided average weight loss of 21% in people…
Novo Nordisks subcutaneous and oral amycretin data published in The Lancet and presented at ADA 2025
Subcutaneous amycretin phase 1b/2a data on the safety, tolerability and weight loss…